# US 2025/0144249 A1 · Methods using surface-expressible activatable epitopes to localize and/or treat diseased cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144249 A1
- Document ID: US20250144249A1
- Status: Published application
- Kind: A1
- Application number: 18/936,497
- Filed: 2024-11-04
- Published: 2025-05-08
- Earliest claimed: 2022-05-04
- Assignees: EARLI Inc.
- Applicants: EARLI Inc.
- Inventors: Alex HARWIG; Evan BISHOP; AMANDA KOHLER; David SUHY
- Web page: https://patentgrep.com/patent/US20250144249A1

## CPC

- A01K 67/027: New or modified breeds of vertebrates
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 38/1709: {from mammals}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 49/14: Peptides, e.g. proteins
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 15/85: for animal cells
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A61K 2123/00: Preparations for testing in vivo
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2800/00: Nucleic acids vectors
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Biomarkers, affinity-based reagents, and methods of using such to detect, image, or treat cancer are described herein.

## Claims

### Claim at position 1

1-60. (canceled)

### Claim 61

A method, comprising:
administering to a subject a composition comprising a nucleic acid encoding an engineered polypeptide, wherein said engineered polypeptide comprises:
(a) an extracellularly-oriented domain comprising an epitope capable of binding: (i) an antibody; or (ii) a peptide hormone or growth factor; wherein said extracellularly-oriented domain does not comprise an scFv; and
(b) a transmembrane domain or membrane affinity domain capable of associating with an outer membrane of a cell, comprising a transmembrane domain or membrane affinity domain from DLL3, PSMA, SSTR2, PD-L1, EGFR, CD28, CD4, ICOS, or CD73,
wherein (a) and (b) are heterologous to each other.

### Claim 62 (depends on 61)

The method of claim 61, wherein said engineered polypeptide does not comprise a light chain variable (VL) domain.

### Claim 63 (depends on 61)

The method of claim 61, wherein said engineered polypeptide does not comprise an intracellular portion of a CD3zeta, CD137, or CD28 polypeptide.

### Claim 64 (depends on 61)

The method of claim 61, wherein said epitope capable of binding: (i) said antibody or (ii) said peptide hormone or growth factor is derived from DLL3, PSMA, SSTR2, or any combination thereof.

### Claim 65 (depends on 64)

The method of claim 64, wherein said epitope is derived from DLL3.

### Claim 66 (depends on 65)

The method of claim 65, wherein said epitope comprises about 15 to about 260 contiguous residues of an extracellular domain of DLL3 having at least 80% identity to SEQ ID NO: 5, or a variant thereof.

### Claim 67 (depends on 64)

The method of claim 64, wherein said epitope comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 4, 5, 19, 20, 64, 65, or a variant thereof.

### Claim 68 (depends on 61)

The method of claim 61, wherein said transmembrane domain or said membrane affinity domain capable of associated with said outer membrane of said cell comprises a sequence having at least 80% sequence identity to a transmembrane domain of any one of SEQ ID NOs: 68-76.

### Claim 69 (depends on 61)

The method of claim 61, wherein said nucleic acid further comprises: (i) an open reading frame (ORF) encoding said engineered polypeptide; (ii) and a promoter operably linked to said ORF.

### Claim 70 (depends on 69)

The method of claim 69, wherein said promoter is: (i) not a T-cell specific promoter; or (ii) not a TCRA, TCRB, CMV, EF-1, hPGK, CD3, or RPBSA promoter.

### Claim 71 (depends on 69)

The method of claim 69, wherein said promoter is a promoter of a gene overexpressed in a cancer cell versus a normal cell, or a functional fragment thereof.

### Claim 72 (depends on 61)

The method of claim 61, wherein said nucleic acid further comprises a vector encoding said engineered polypeptide, wherein said vector comprises a nanoplasmid vector, a close-ended linear duplex (CELiD) vector, or a Doggybone DNA vector (dbDNA).

### Claim 73 (depends on 72)

The method of claim 72, wherein said vector comprises a nanoplasmid vector.

### Claim 74 (depends on 73)

The method of claim 73, wherein a nanoplasmid vector comprises a minimized bacterial Co1E1 or R6K origin of replication and a bacterial RNA-based selectable marker.

### Claim 75 (depends on 61)

The method of claim 61, further comprising administering to said subject an antibody or antigen-binding fragment thereof, a protein ligand or functional fragment thereof, or a small molecule configured to bind said epitope.

### Claim 76 (depends on 75)

The method of claim 75, wherein said antibody or antigen-binding fragment thereof, said protein ligand or said functional fragment thereof, or said small molecule configured to bind said epitope is administered intravenously.

### Claim 77 (depends on 75)

The method of claim 75, wherein: (i) said administering to said subject said composition comprising said nucleic acid; and (ii) said administering to said subject said antibody or antigen-binding fragment, said protein ligand or functional fragment thereof, or said small molecule configured to bind said epitope are separated by 96 hours or less.

### Claim 78 (depends on 75)

The method of claim 75, further comprising detecting binding of said antibody or antigen binding fragment, said protein ligand or functional fragment thereof, or said small molecule to said epitope.

### Claim 79 (depends on 78)

The method of claim 78, further comprising detecting binding of said antibody or antigen binding fragment, said protein ligand or functional fragment thereof, or said small molecule to said epitope via a non-invasive imaging method.

### Claim 80 (depends on 79)

The method of claim 79, wherein said non-invasive imaging method is performed 120 hours or less after administering to said subject said antibody or antigen-binding fragment, said protein ligand or functional fragment thereof, or said small molecule configured to bind said epitope.

### Claim 81 (depends on 75)

The method of claim 75, wherein said antibody or antigen binding fragment thereof or said protein ligand or functional fragment thereof further comprises a radioisotope.

### Claim 82 (depends on 81)

The method of claim 81, wherein said radioisotope is a positron-emitting radioisotope.

### Claim 83 (depends on 79)

The method of claim 79, wherein said non-invasive imaging method comprises positron emission tomography (PET).

### Claim 84 (depends on 75)

The method of claim 75, wherein said antibody or antigen binding fragment thereof or said protein ligand or functional fragment thereof further comprises a magnetic resonance imaging (MRI) contrast agent.

### Claim 85 (depends on 84)

The method of claim 84, wherein said non-invasive imaging method comprises MRI.

### Claim 86 (depends on 75)

The method of claim 75, wherein said antibody or antigen binding fragment thereof or said protein ligand or functional fragment thereof comprises an antibody or antigen binding fragment thereof.

### Claim 87 (depends on 86)

The method of claim 86, wherein said antibody or antigen binding fragment thereof comprises an antibody drug conjugate (ADC).

### Claim 88 (depends on 61)

The method of claim 61, wherein said engineered polypeptide comprises an extracellularly-oriented polypeptide spacer domain of about 15 to about 40 angstroms in length when folded between (a) and (b)

### Claim 89 (depends on 88)

The method of claim 88, wherein said extracellularly-oriented polypeptide spacer domain comprises a hinge sequence from IgG4, IgG1, IgG2, IgG3, IgK, CD4, or CD28, or any combination thereof.

### Claim 90 (depends on 88)

The method of claim 88, wherein said extracellularly-oriented polypeptide spacer domain comprises a hinge sequence having at least 80% sequence identity to a hinge sequence of any one of SEQ ID NOs: 58, 59, 60, 61, 62, 66, 67, or a variant thereof.
